BPG is committed to discovery and dissemination of knowledge
Featured Articles
10/28/2019 9:39:29 AM | Browse: 689 | Download: 1561
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 48667
Country Italy
ISSN 1948-5204 (online)
Open Access This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Review
Article Title Targeted agents for second-line treatment of advanced hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Nicola Personeni, Tiziana Pressiani, Silvia Bozzarelli and Lorenza Rimassa
Funding Agency and Grant Number
Corresponding Author Lorenza Rimassa, MD, Adjunct Professor, Chief Doctor, Humanitas Cancer Center, Humanitas Clinical and Research Center, IRCCS, via Manzoni 56, Rozzano 20089, Milan, Italy. lorenza.rimassa@cancercenter.humanitas.it
Key Words Hepatocellular carcinoma; Advanced-metastatic; Second-line; Third-line; Regorafenib; Cabozantinib
Core Tip During the last decade, sorafenib, a multikinase inhibitor, has emerged as the only systemic agent available for the treatment of patients with unresectable hepatocellular carcinoma. However, in recent years, lenvatinib, which is a different multikinase inhibitor, was shown to be non-inferior compared to sorafenib. Despite several negative phase III trials, novel drugs with similar, but not overlapping, properties have been recently shown to improve patient outcomes, thereby confirming the role of a sustained anti-angiogenic inhibition in further lines of treatment. Here, we will discuss the results of the positive phase III trials of regorafenib, cabozantinib, and ramucirumab in patients failing sorafenib.
Publish Date 2019-10-16 12:17
Citation Personeni N, Pressiani T, Bozzarelli S, Rimassa L. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(10): 788-803
URL https://www.wjgnet.com/1948-5204/full/v11/i10/788.htm
DOI https://dx.doi.org/10.4251/wjgo.v11.i10.788
Full Article (PDF) WJGO-11-788.pdf
Full Article (Word) WJGO-11-788.docx